CVS Stock Recent News

Live Updates Live Coverage Has Ended Goldman's Warning 2:30 pm by Gerelyn Terzo Wall Street firm Goldman Sachs believes there’s still another shoe yet to drop in the trade wars despite progress made between the White House and Beijing. The analyst firm wrote: “The large reduction in the U.S. tariff rate on China should only have a limited impact on the overall U.S. effective tariff rate. After accounting for a reduction of that magnitude, the full set of U.S. tariffs would still be considerably higher and broader than expected by markets at the start of the year.” Winners & Losers 12:12 pm by Gerelyn Terzo With today’s market rally, the S&P 500 has narrowed its year-to-date declines to 1.3%. Within the S&P 500, today’s biggest gainers include NRG Energy (NYSE: NRG), up 23%, Stanley Black & Decker (NYSE: SWK), up 14.4%, and Microchip Tech (Nasdaq: MCHP), up 11.2%. Among the biggest losers of today’s session include Cigna Group (NYSE: CI),

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

The South Main Street CVS Pharmacy is again providing health, wellness and pharmacy services to customers and patients WOONSOCKET, R.I. , May 12, 2025 /PRNewswire/ -- Today, leaders from CVS Health® (NYSE: CVS) were joined by state and local representatives to celebrate the reopening of one of its Hendersonville CVS Pharmacy stores.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.

CVS Health has shown impressive year-to-date performance, driven by strong Q1 results and strategic shifts in its business model. I reiterate a buy rating on CVS due to its low valuation, mixed technicals, and promising earnings growth prospects. Key catalysts include improved performance in Healthcare Benefits, higher star ratings in Medicare Advantage, and strategic exits from less profitable areas.

CVS' turnaround may be here, given the seemingly stabilizing medical cost trends as similarly reported by its peers, with it triggering the moderating Medical Benefit Ratio. This is despite the stable enrollments and the higher utilization, thanks to its improved Medicare Advantage star ratings and the growth in its commercial-fee businesses. We are likely to see CVS' Health Care Benefits segment report sequential improvements after the exit from the Affordable Care Act [ACA] plans from 2026 onwards as well.

Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).